Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 21 2013
Print RSS Feed

Breaking News

Related Searches: Financial Reports •
Financial Report: PAREXEL 2Q

January 27, 2009
Consolidated service revenue for the quarter was $200.9 million in Clinical Research Services (CRS), $31.9 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $43.0 million in Perceptive Informatics, Inc.  Read More »
Financial Report: Amgen 4Q

January 27, 2009
Product sales were up 2% to $3.7 billion in the quarter. Sales in the U.S. were up 1%, to $2.9 billion, while international sales increased 4% to $774 million.  Read More »
Astellas Makes Offer for CV Therapeutics

January 27, 2009
Astellas Pharma has submitted a proposal to the board of directors of CV Therapeutics, Inc. to acquire all outstanding shares of CV Therapeutics at a total value of $1.0 billion in cash.  Read More »
Pfizer To Acquire Wyeth

January 26, 2009
Pfizer will buy Wyeth for $68 billion in cash and stock.  Read More »
Financial Report: Wyeth 4Q

January 26, 2009
Wyeth 4Q08 4Q Revenues: $5.3 billion (-7%) 4Q Earnings: $960 million (-5%) FY Revenues: $22.8 billion (+2%) FY Earnings: $4.4 billion (-2%) Comments: Revenues dropped as Effexor sales fell 7% to $902 million in 4Q08. For the year, Effe…  Read More »
Financial Report: Pfizer 4Q08

January 26, 2009
Pfizer 4Q08 4Q Revenues: $12.3 billion (-4%) 4Q Earnings: $266 million (-96%) FY Revenues: $48.3 billion (flat) FY Earnings: $8.1 billion (flat) Comments: Generic losses continued to dent Pfizer's sales: Zyrtec, Camptosar and Norvasc r…  Read More »
AMRI

January 26, 2009
Michael D. Ironside, Ph.D. has been named director of global project management at AMRI. In this newly created role, Dr. Ironside will be responsible for overseeing all project management activities related to products moving through AMRI’s pha…  Read More »
GSK Buys Emerging Operations from UCB

January 23, 2009
UCB has agreed to sell its UCB business and affiliates in selected emerging markets to GlaxoSmithKline for $670 million in cash. The transaction is expected to close in 1Q09. The commercial operations and product distribution rights acquired by GSK r…  Read More »
Merck Serono's Oral MS Drug Meets Trial Endpoints

January 23, 2009
Merck Serono's Phase III CLARITY trial of its oral formulation of cladribine met the two-year primary endpoint of clinical relapse rate reduction in patients with relapsing-remitting multiple sclerosis (MS).       The two…  Read More »
Alnylam's Liver Cancer Drug Cleared for Phase I Study

January 23, 2009
Alnylam Pharmaceuticals' IND application for ALN-VSP has been cleared by the FDA to begin enrolling patients in a Phase I trial. ALN-VSP, an RNAi therapeutic for the treatment of liver cancers, including hepatocellular carcinoma and other solid tumor…  Read More »
OSO BioPharmaceuticals Manufacturing

January 22, 2009
Rick Lapointe has been appointed vice president of technology and acquisitions at OSO BioPharmaceuticals Manufacturing. Mr. Lapointe will be responsible for working with the senior leadership team to increase the company’s capabilities, identif…  Read More »
PII Launches Drug Delivery Solutions

January 22, 2009
PII, (Pharmaceutics International, Inc.) has launched PII Drug Delivery Solutions to provide clients with product development tools to help meet the challenges of new chemical entities (NCEs) and product life cycle management (LCM). The goal of P…  Read More »
Stelara Approved in Europe for Plaque Psoriasis

January 22, 2009
Janssen-Cilag received approval from the European Commission for Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or are intolerant to other systemic therapies including ciclosporin, m…  Read More »
Financial Report: Abbott 4Q

January 21, 2009
Abbott   4Q Revenues: $8.0 billion (+10%) 4Q Earnings: $1.5 billion (+28%) FY Revenues: $30.0 billion (+14%) FY Earnings: $4.9 billion (+35%) Comments: Worldwide pharmaceutical sales were up 10% to $4.6 billion in the quarter, and…  Read More »
Roche RA Drug Approved in Europe

January 21, 2009
Roche received approval from the European Commission for RoActemra (tocilizumab, known as Actemra outside of the EU), to treat patients with rheumatoid arthritis (RA). RoActemra, in combination with methotrexate (MTX), is indicated for the treatment…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: